The COVID-19 pandemic prompted a transformation in the infectious disease point-of-care testing (POCT) market. The shift towards miniaturized POCT devices will lead to the emergence of cost-effective integrated lab-on-a-chip devices based on microfluidic technologies and smartphone-based solutions enabling multiplexed detection of infectious pathogens. From RT-PCR to serology tests, and the beginning of new CRISPR-based diagnostics powered by artificial intelligence and machine learning algorithms, a high degree of sensitivity and specificity is possible. This shift is fostering notable market growth driven further by the possibility of alternate care sites that will provide more affordable and accessible point-of-care diagnostic tests.
Genomics are expected to drive the innovation spectrum in this space, changing the paradigm of understanding host-pathogen interaction, creating opportunity for more personalized prevention. CRISPR-based diagnostic tests to detect SARS-CoV-2 have shown a specificity and sensitivity of 100% on clinical patients, and it is only a matter of time before such tests are implemented at a POC setting.